ALNYLAM PHARMACEUTICALS INC

Alnylam Shares Drop 2.43% as Investors Reassess RNA‑Silencing Risk

Alnylam shares fall 2.43%, reflecting investor wariness over pipeline delays, competition, and macro‑economic headwinds.

ALNYLAM PHARMACEUTICALS INC
United States
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

Vanessa Liu

23/10/2026, 04:08

3 minutes to read

Alnylam’s Phase‑III Hypertriglyceridemia Breakthrough Signals Strong Future Growth in RNA Therapy

Alnylam’s 2026 trading trend reflects its promising RNA‑based pipeline for severe hypertriglyceridemia, showing a phase‑III ASO breakthrough that could reshape lipid‑disorder treatment.

ALNYLAM PHARMACEUTICALS INC
United States
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

Jake Connors

21/10/2026, 21:01

4 minutes to read